These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 6477838

  • 1. Depletion of excessive liver iron stores with desferrioxamine.
    Cohen A, Martin M, Schwartz E.
    Br J Haematol; 1984 Oct; 58(2):369-73. PubMed ID: 6477838
    [Abstract] [Full Text] [Related]

  • 2. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.
    Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Laulicht M, Fenton LA, Scheuer PJ, Kibbler CC, Allwood CA, Brown D.
    J Clin Pathol; 1987 Nov; 40(11):1353-9. PubMed ID: 3121679
    [Abstract] [Full Text] [Related]

  • 3. Response to long-term deferoxamine therapy in thalassemia.
    Cohen A, Martin M, Schwartz E.
    J Pediatr; 1981 Nov; 99(5):689-94. PubMed ID: 7299539
    [Abstract] [Full Text] [Related]

  • 4. Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia.
    Risdon RA, Barry M, Flynn DM.
    J Pathol; 1975 Jun; 116(2):83-95. PubMed ID: 1151528
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Iron chelation in thalassemia: mechanism of desferrioxamine action.
    Hershko C, Rachmilewitz EA.
    Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
    [Abstract] [Full Text] [Related]

  • 7. Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia.
    Giardini C, Galimberti M, Lucarelli G, Polchi P, Angelucci E, Baronciani D, Gaziev D, Erer B, La Nasa G, Barbanti I.
    Br J Haematol; 1995 Apr; 89(4):868-73. PubMed ID: 7772524
    [Abstract] [Full Text] [Related]

  • 8. A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study.
    Maurer HS, Lloyd-Still JD, Ingrisano C, Gonzalez-Crussi F, Honig GR.
    Am J Dis Child; 1988 Mar; 142(3):287-92. PubMed ID: 3344715
    [Abstract] [Full Text] [Related]

  • 9. Early iron overload in beta-thalassaemia major: when to start chelation therapy?
    Fargion S, Taddei MT, Gabutti V, Piga A, Di Palma A, Capra L, Fontanelli G, Avanzini A.
    Arch Dis Child; 1982 Dec; 57(12):929-33. PubMed ID: 7181522
    [Abstract] [Full Text] [Related]

  • 10. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia.
    Cossu P, Toccafondi C, Vardeu F, Sanna G, Frau F, Lobrano R, Cornacchia G, Nucaro A, Bertolino F, Loi A, De Virgiliis S, Cao A.
    Eur J Pediatr; 1981 Nov; 137(3):267-71. PubMed ID: 7318837
    [Abstract] [Full Text] [Related]

  • 11. Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.
    De Virgiliis S, Cossu P, Sanna G, Frau F, Loi E, Lobrano R, Nucaro A, Toccafondi C, Cornacchia G, Loi A, Cao A.
    Acta Haematol; 1982 Nov; 67(1):49-56. PubMed ID: 6800202
    [Abstract] [Full Text] [Related]

  • 12. Long-term desferrioxamine therapy in thalassemia.
    Modell CB, Beck J.
    Ann N Y Acad Sci; 1974 Nov; 232(0):201-10. PubMed ID: 4528634
    [No Abstract] [Full Text] [Related]

  • 13. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Nov; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 14. Sustained normalization of cardiac function by chelation therapy in thalassaemia major.
    Freeman AP, Giles RW, Berdoukas VA, Talley PA, Murray IP.
    Clin Lab Haematol; 1989 Nov; 11(4):299-307. PubMed ID: 2605872
    [Abstract] [Full Text] [Related]

  • 15. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R, Piga A, Harmatz P, Nielsen P.
    Ann N Y Acad Sci; 2005 Nov; 1054():350-7. PubMed ID: 16339683
    [Abstract] [Full Text] [Related]

  • 16. Mechanism of desferrioxamine-induced iron excretion in thalassaemia.
    Hershko C, Rachmilewitz EA.
    Br J Haematol; 1979 May; 42(1):125-32. PubMed ID: 465354
    [No Abstract] [Full Text] [Related]

  • 17. The effect of desferrioxamine chelation versus no therapy in patients with non transfusion-dependent thalassaemia: a multicenter prospective comparison from the MIOT network.
    Ricchi P, Meloni A, Pistoia L, Spasiano A, Spiga A, Allò M, Gamberini MR, Lisi R, Campisi S, Peluso A, Missere M, Renne S, Mangione M, Positano V, Pepe A.
    Ann Hematol; 2018 Oct; 97(10):1925-1932. PubMed ID: 29926157
    [Abstract] [Full Text] [Related]

  • 18. The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B.
    Bayraktar Y, Saglam F, Temizer A, Uzunalimodlu B, van Thiel DH.
    Hepatogastroenterology; 1998 Oct; 45(24):2322-7. PubMed ID: 9951916
    [Abstract] [Full Text] [Related]

  • 19. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA.
    N Engl J Med; 1998 Aug 13; 339(7):417-23. PubMed ID: 9700174
    [Abstract] [Full Text] [Related]

  • 20. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I, Hatzidimitriou-Papazacharia K, Spiliotopoulou J, Tsagarakis N, Digenopoulou E.
    Birth Defects Orig Artic Ser; 1988 Aug 13; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.